Roche Holding AG (RHHBY)
| Market Cap | 236.43B |
| Revenue (ttm) | 67.42B |
| Net Income (ttm) | 11.82B |
| Shares Out | n/a |
| EPS (ttm) | 14.73 |
| PE Ratio | 20.01 |
| Forward PE | n/a |
| Dividend | 0.85 (2.33%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 4,197,000 |
| Average Volume | 1,660,391 |
| Open | 36.33 |
| Previous Close | 36.67 |
| Day's Range | 36.05 - 36.45 |
| 52-Week Range | 29.20 - 42.43 |
| Beta | 0.15 |
| RSI | 55.41 |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial numbers in CHF Financial StatementsNews
Roche descendant André Hoffmann on pharma, feuds and family business
Davos trustee and ESG backer takes stand against ‘arrogance’ of Trump and Musk
B-cell Depletion Innovation Research Report 2024: Roche Dominate the Patent Activity in B-cell Depletion Therapy, with a Dip in New Companies Filing Patents in Recent Years
Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: B-cell Depletion" report has been added to ResearchAndMarkets.com's offering.
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. (NASDAQ: OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degene...
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics announces exercise of option by Roche for next-generation AAV vector for neurological gene therapy.
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma su...
Danielle Dysinger: Engineering Creativity, Advocacy, and the Great Outdoors
Danielle Dysinger is an engineer, entrepreneur, and passionate advocate based in Tucson, Arizona. A graduate of the University of Arizona with a degree in chemical engineering, Danielle has built a dy...
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win
Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images. ...
Roche to close $1.5B acquisition of Poseida Therapeutics
Discover the latest news and updates on Roche Diagnostics with insights on their Silicon Valley campus facade.
Roche to complete acquisition of U.S. biopharma company Poseida
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and no...
Roche Vabysmo Sales Surpassed USD 4 Billion In 2024
Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche, Innovent ink licensing deal for lung cancer drug
Innovent Biologics Inc (IVBIY) Partners with Roche for Novel DLL3 Antibody Drug Conjugate
Innovent Biologics Inc (IVBIY) Partners with Roche for Novel DLL3 Antibody Drug Conjugate
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
SAN FRANCISCO and SUZHOU, China , Jan. 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
Roche CEO Reassures No Job Cuts Despite Challenges: Report
Swiss pharmaceutical giant Roche Holding AG (OTC: RHHBY) reportedly has no plans for job cuts despite facing recent challenges in its drug development pipeline. CEO Thomas Schinecker, in an interview...
Roche Maintains Stability – CEO Thomas Schinecker Assures Workforce Levels Will Not Drop
Swiss pharmaceutical giant Roche remains on solid footing with no immediate plans for job reductions, according to recent statements by CEO Thomas Schinecker in a Swiss newspaper interview. While the ...
Roche CEO Confirms No Layoffs Amidst Business Stability
Roche CEO Confirms No Layoffs Amidst Business Stability
Roche CEO says no job cuts planned, business is healthy: report
Roche Holding CEO Thomas Schinecker reassures no job cuts planned, discusses future drug launches and economic challenges in Europe, US, and China.
Roche has no plans for job cuts and business is healthy, CEO says
Swiss pharmaceutical company Roche is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.
Health global capability centres grapple with unhealthy gender ratio
Healthcare-focused global capability centres struggle with gender diversity, with only 28% women in the workforce, and just 15% in R&D roles. Companies like Roche, Siemens Healthineers, and Merck attr...
Experts gather in Hong Kong to tackle liver cancer together
[The content of this article has been produced by our advertising partner.] The LEAD event brings together top liver disease experts across APAC, providing a vital platform for advancing liver disease...
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena and Roche report Phase 2b PADOVA ... Full story available on Benzinga.com
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
An experimental Parkinson's drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.